Merck & Co., Inc. $MRK Stock Holdings Raised by Keebeck Wealth Management

Keebeck Wealth Management grew its stake in Merck & Co., Inc. (NYSE:MRK) by 17.8% during the first quarter, HoldingsChannel.com reports. The firm owned 31,081 shares of the company’s stock after purchasing an additional 4,697 shares during the period. Keebeck Wealth Management’s holdings in Merck & Co., Inc. were worth $3,765,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of MRK. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. in the fourth quarter valued at about $25,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new position in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the 4th quarter worth approximately $31,000. Finally, High Note Wealth LLC grew its position in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a report on Monday, July 6th. Morgan Stanley raised their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. CICC Research began coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Finally, Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.94.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $130.57 on Friday. The company has a market cap of $322.49 billion, a P/E ratio of 36.78, a PEG ratio of 5.08 and a beta of 0.19. The business has a 50 day moving average of $121.27 and a two-hundred day moving average of $117.62. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $131.74. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.